News
Touchlight signs patent agreement with Pfizer
Touchlight, a company which focuses on enzymatic DNA production to further advance genetic medicines, has announced a significant non-exclusive patent licence agreement with pharma giants, Pfizer.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Touchlight, a company which focuses on enzymatic DNA production to further advance genetic medicines, has announced a significant non-exclusive patent licence agreement with pharma giants, Pfizer.